Skip to content

QUARTET FAPL: value indication

Line	Code	2024	2025	Change	%
Total assets	20/58	€516,829	€518,139	+€1,309	+0.3%
Fixed assets	21/28	€514,775	€489,700	-€25,075	-4.9%
Tangible fixed assets	22/27	€514,775	€489,700	-€25,075	-4.9%
Land and buildings	22	€514,775	€88,500	-€426,275	-82.8%
Plant, machinery and equipment	23	-	€401,200	+€401,200
Current assets	29/58	€2,054	€28,439	+€26,384	+1,284%
Amounts receivable within one year	40/41	€2,054	€26,210	+€24,155	+1,176%
Trade receivables	40	-	€24,200	+€24,200
Other amounts receivable	41	€2,054	€2,010	-€45	-2.2%
Cash at bank and in hand	54/58	-	€2,229	+€2,229
Total equity and liabilities	10/49	€516,829	€518,139	+€1,309	+0.3%
Equity	10/15	€490,802	€497,801	+€6,999	+1.4%
Contributions	10/11	€592,000	€592,000	=	0.0%
Capital	10	€592,000	-	-€592,000
Issued capital	100	€592,000	-	-€592,000
Profit (loss) carried forward	14	-€101,198	-€94,199	+€6,999	+6.9%
Amounts payable	17/49	€26,027	€20,338	-€5,690	-21.9%
Amounts payable within one year	42/48	€21,188	€20,338	-€850	-4.0%
Taxes, remuneration and social security	45	-	€3,150	+€3,150
Taxes	450/3	-	€3,150	+€3,150
Other amounts payable	47/48	€21,188	€17,188	-€4,000	-18.9%
Accrued charges and deferred income	492/3	€4,840	-	-€4,840
Goods, raw materials, services and sundry goods	60/61	€11,240	-	-€11,240
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets	630	€25,075	€25,075	=	0.0%
Gross operating margin	9900	-€11,240	€32,074	+€43,314
Operating profit (loss)	9901	-€36,315	€6,999	+€43,314
Profit (loss) for the period before taxes	9903	-€36,315	€6,999	+€43,314
Profit (loss) for the period	9904	-€36,315	€6,999	+€43,314
Profit (loss) for the period to be appropriated	9905	-€36,315	€6,999	+€43,314

QUARTET FAPL: value indication

QUARTET FAPL: value indication

Position among the sector peers

What moved between 2024 and 2025

Largest movements

Change in the result, 2024 to 2025

Derived cash bridge

Value

Indicative value of the equity

Adjusted equity

Capitalised earnings

Your EBITDA multiple

Limits of the indication

Next steps